Publications by authors named "Patricia Camo"
Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry.
Therap Adv Gastroenterol
January 2024
Article Synopsis
- Infliximab is considered the most effective anti-TNF treatment for ulcerative colitis (UC), but there is limited information on its use as a second anti-TNF option.
- This study analyzed 473 UC patients to compare outcomes between those receiving their first anti-TNF treatment via intravenous (IV) versus subcutaneous (SC) routes.
- Results showed similar clinical response and remission rates after 14 and 52 weeks, suggesting that while a second anti-TNF can be effective, prior failure of the first anti-TNF significantly impacts long-term success.
Background: Both vedolizumab and ustekinumab are approved for the management of Crohn's disease [CD]. Data on which one would be the most beneficial option when anti-tumour necrosis factor [anti-TNF] agents fail are limited.
Aims: To compare the durability, effectiveness, and safety of vedolizumab and ustekinumab after anti-TNF failure or intolerance in CD.
Background: Patients with gastrointestinal bleeding during anticoagulant and/or antiplatelet therapy represent a clinical challenge.
Aim: To determine the risk/rates of rebleeding, vascular events and death in patients treated with antiplatelet or anticoagulant agents who developed major gastrointestinal bleeding METHODS: This was an observational cohort study of patients who developed gastrointestinal bleeding while on antiplatelet and/or anticoagulant therapy. Drug use information was collected prospectively during bleeding events.
Article Synopsis
- Primary sclerosing cholangitis (PSC) is often linked with inflammatory bowel disease (IBD) and is associated with a higher risk of cancers, especially colorectal cancer (CRC) and cholangiocarcinoma (CCA).
- A study of 277 PSC-IBD patients revealed a PSC incidence rate of 61 cases per 100,000 IBD patient-years, with the majority treated using ursodeoxycholic acid and some requiring liver transplants.
- The findings indicate that PSC symptoms at diagnosis increase CRC risk, with CCA found primarily in patients with intra- and extrahepatic PSC, leading to poorer survival compared to those without CCA.
Background: Effectiveness of vedolizumab in real world clinical practice is unknown.
Aim: To evaluate the short and long-term effectiveness of vedolizumab in patients with inflammatory bowel disease (IBD).
Methods: Patients who received at least 1 induction dose of vedolizumab were included.